Literature DB >> 17020320

Synthesis and evaluation of coumermycin A1 analogues that inhibit the Hsp90 protein folding machinery.

Joseph A Burlison1, Brian S J Blagg.   

Abstract

[structure: see text] The coumarin antibiotics are not only potent inhibitors of DNA gyrase but also represent the most effective C-terminal inhibitors of 90 kDa heat shock proteins (Hsp90) reported thus far. In contrast to the N-terminal ATP-binding site, little is known about the Hsp90 C-terminus. In addition, very limited structure-activity relationships exist between this class of natural products and Hsp90. In this letter, the syntheses of dimeric coumarin analogues are presented along with their inhibitory values in breast cancer cell lines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17020320     DOI: 10.1021/ol061918j

Source DB:  PubMed          Journal:  Org Lett        ISSN: 1523-7052            Impact factor:   6.005


  31 in total

1.  High-throughput assay for the identification of Hsp90 inhibitors based on Hsp90-dependent refolding of firefly luciferase.

Authors:  Lakshmi Galam; M Kyle Hadden; Zeqiang Ma; Qi-Zhuang Ye; Bo-Geon Yun; Brian S J Blagg; Robert L Matts
Journal:  Bioorg Med Chem       Date:  2007-01-04       Impact factor: 3.641

2.  Cytotoxic small molecule dimers and their inhibitory activity against human breast cancer cells.

Authors:  M Kyle Hadden; Brian S J Blagg
Journal:  Bioorg Med Chem Lett       Date:  2007-07-13       Impact factor: 2.823

3.  Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors.

Authors:  Bhaskar Reddy Kusuma; Adam S Duerfeldt; Brian S J Blagg
Journal:  Bioorg Med Chem Lett       Date:  2011-10-01       Impact factor: 2.823

4.  Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors.

Authors:  Takrima Sadikot; Megan Swink; Jeffery D Eskew; Douglas Brown; Huiping Zhao; Bhaskar R Kusuma; Roger A Rajewski; Brian S J Blagg; Robert L Matts; Jeffrey M Holzbeierlein; George A Vielhauer
Journal:  Assay Drug Dev Technol       Date:  2013-10-15       Impact factor: 1.738

5.  Novologues containing a benzamide side chain manifest anti-proliferative activity against two breast cancer cell lines.

Authors:  Huiping Zhao; Mercy Anyika; Antwan Girgis; Brian S J Blagg
Journal:  Bioorg Med Chem Lett       Date:  2014-05-16       Impact factor: 2.823

Review 6.  New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.

Authors:  Yanyan Li; Tao Zhang; Steven J Schwartz; Duxin Sun
Journal:  Drug Resist Updat       Date:  2009 Feb-Apr       Impact factor: 18.500

7.  Synthesis and evaluation of a ring-constrained Hsp90 C-terminal inhibitor that exhibits neuroprotective activity.

Authors:  Zheng Zhang; Zhenyuan You; Rick T Dobrowsky; Brian S J Blagg
Journal:  Bioorg Med Chem Lett       Date:  2018-03-26       Impact factor: 2.823

Review 8.  Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.

Authors:  Alison Donnelly; Brian S J Blagg
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

9.  Gyrase B inhibitor impairs HIV-1 replication by targeting Hsp90 and the capsid protein.

Authors:  Luciano Vozzolo; Belinda Loh; Paul J Gane; Maryame Tribak; Lihong Zhou; Ian Anderson; Elisabeth Nyakatura; Richard G Jenner; David Selwood; Ariberto Fassati
Journal:  J Biol Chem       Date:  2010-10-11       Impact factor: 5.157

10.  The synthesis and evaluation of flavone and isoflavone chimeras of novobiocin and derrubone.

Authors:  Jared R Mays; Stephanie A Hill; Justin T Moyers; Brian S J Blagg
Journal:  Bioorg Med Chem       Date:  2009-10-31       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.